Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non?exclusive sub?licensing agreement to co?market sodium glucose co?transporter?2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
Under the terms of the agreement, the company will receive an upfront payment, license fees and royalties for the non?exclusive sub?license rights from Torrent. The company will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ in India.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
